From the Editor

Jun 09, 2017
Pharmaceutical Executive
There's no shortage of talent, expertise and passion in the biopharma industry. It's time for that talent to shine, writes Lisa Henderson.
May 04, 2017
Pharmaceutical Executive
Recent PR disasters in other industries raise an important reputational question that can apply to pharma as well: do you want to be someone that works the system or improves the system?
Apr 06, 2017
Pharmaceutical Executive
Two topics in Pharm Exec this month—rare disease research and women in healthcare leadership—share a "common" thread.
Mar 09, 2017
Pharmaceutical Executive
No longer just hype, investing in big data is the path to the future for pharma, even if big returns aren't a direct result, writes Pharm Exec Editor Lisa Henderson.
Feb 08, 2017
Pharmaceutical Executive
Here's to hoping that PhRMA's new public education campaign advances the voice of the patient in its messaging.
Dec 09, 2016
Pharmaceutical Executive
Despite industry's success in translating discovery research into products with proven clinical value, it continues to struggle in positioning medical research to the public as a distinctive force for good, writes William Looney.
Nov 07, 2016
Pharmaceutical Executive
The influx of treatment breakthroughs and expanding science has not silenced the debate over the productivity of biopharma's R&D model, and the looming challenges for R&D decision-makers.
Oct 11, 2016
Pharmaceutical Executive
Highlighting the seven key trends in global pharma that drove discussion at this year's CPhI Worldwide event in Spain.
Sep 07, 2016
Pharmaceutical Executive
Big pharma has become increasingly vulnerable to larger geopolitical and macroeconomic risks—a realization that has slowly creeped into their business planning, writes William Looney.
Jul 13, 2016
Pharmaceutical Executive
Amid today's growing constituency of cancer survivors, oncology is testing the historic divide in medicine between what’s science and what’s social, writes William Looney.
lorem ipsum